Financials Oscotec Inc.

Equities

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
42,600 ^KRW	-1.84%		-1.16%	+84.82%

Feb. 23	Oscotec/Adel Initiates First-In-Human Dosing in Ph1 of Anti-Mtbr Tau Antibody Adel-Y01 in Alzheimer's Disease	CI
2023	Oscotec Inc. and ADEL Inc. Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	714,757	1,970,207	1,110,134	655,533	880,167	1,626,783	-	-
Enterprise Value (EV) ²	714.8	1,944	1,102	655.5	807.3	1,548	1,520	1,473
P/E ratio	-27.1 x	-423 x	-	-22.7 x	-	-	-	-
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	164 x	45.3 x	284 x	-	178 x	38.3 x	19.6 x	14.5 x
EV / Revenue	164 x	44.7 x	282 x	-	163 x	36.4 x	18.3 x	13.1 x
EV / EBITDA	-	787 x	-36.5 x	-	-26.1 x	310 x	36.2 x	23 x
EV / FCF	-	-97.1 x	-	-	-35.7 x	-1,032 x	51.5 x	31 x
FCF Yield	-	-1.03%	-	-	-2.8%	-0.1%	1.94%	3.23%
Price to Book	-	36.4 x	-	-	8.85 x	16.6 x	12.9 x	9.42 x
Nbr of stocks (in thousands)	29,658	30,034	30,332	37,892	38,185	38,187	-	-
Reference price ³	24,100	65,600	36,600	17,300	23,050	42,600	42,600	42,600
Announcement Date	3/6/20	2/3/21	2/9/22	3/17/23	3/18/24	-	-	-

¹KRW in Million²KRW in Billions³KRW

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	4.369	43.47	3.903	-	4.951	42.5	83	112.5
EBITDA ¹	-	2.469	-30.18	-	-30.9	5	42	64
EBIT ¹	-	1.58	-31.5	-	-32.66	3.5	40.5	62.5
Operating Margin	-	3.64%	-807.04%	-	-659.58%	8.24%	48.8%	55.56%
Earnings before Tax (EBT)	-	1.293	-	-	-	-	-	-
Net income	-	-4.357	-	-24.43	-	-	-	-
Net margin	-	-10.02%	-	-	-	-	-	-
EPS	-890.0	-155.0	-	-763.0	-	-	-	-
Free Cash Flow ²	-	-20,014	-	-	-22,626	-1,500	29,500	47,500
FCF margin	-	-46,039.79%	-	-	-456,996.99%	-3,529.41%	35,542.17%	42,222.22%
FCF Conversion (EBITDA)	-	-	-	-	-	-	70,238.1%	74,218.75%
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	3/6/20	2/3/21	2/9/22	3/17/23	3/18/24	-	-	-

¹KRW in Billions²KRW in Million

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	-	-	-	-
Net Cash position ¹	-	26.5	7.64	-	72.9	79	107	154
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ²	-	-20,014	-	-	-22,626	-1,500	29,500	47,500
ROE (net income / shareholders' equity)	-	-4.05%	-	-	-21.9%	2.2%	24.6%	30.4%
ROA (Net income/ Total Assets)	-	-3.08%	-	-	-	1.9%	6.9%	21.8%
Assets	-	141.5	-	-	-	-	-	-
Book Value Per Share ³	-	1,800	-	-	2,604	2,560	3,312	4,520
Cash Flow per Share ³	-	-612.0	-	-	-	145.0	361.0	1,124
Capex ¹	-	2.13	-	-	-	1	1	1
Capex / Sales	-	4.91%	-	-	-	2.35%	1.2%	0.89%
Announcement Date	3/6/20	2/3/21	2/9/22	3/17/23	3/18/24	-	-	-

¹KRW in Billions²KRW in Million³KRW

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42,600 KRW

Average target price

56,000 KRW

Spread / Average Target

+31.46%

	1st Jan change	Capi.
OSCOTEC INC.	+84.82%	1.2B
KYOWA KIRIN CO. LTD.	+34.09%	10.31B
YUHAN CORPORATION	+40.41%	5.23B
SK BIOPHARMACEUTICALS CO., LTD.	-15.24%	4.62B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+11.62%	3.52B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+26.25%	2.31B
BETTA PHARMACEUTICALS CO., LTD.	-38.78%	1.78B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-44.54%	1.69B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B
SUPERNUS PHARMACEUTICALS, INC.	+0.47%	1.59B